Research summary
Ipamorelin has been studied in animal models and in early clinical research on growth hormone release, and it is not an approved medicine. This summary describes what the literature has investigated. It is not a claim about the effects of our product, which is supplied for laboratory research only.
Mechanism of action
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a). In published work it stimulates growth hormone release from pituitary cells with little effect on cortisol or prolactin compared with some other secretagogues.
Chemical properties
Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2 (5 residues, C-terminal amide). Molecular formula: C38H49N9O5. Molecular weight: approx. 711.9 g/mol. Form: lyophilised powder. Purity and identity: see the batch Certificate of Analysis (HPLC and mass spectrometry).
Storage and handling
Supplied as a lyophilised (freeze-dried) powder. Store sealed, cold, dry and protected from light, as stated on the Certificate of Analysis and product label. Allow the vial to reach room temperature before opening to limit condensation. Avoid repeated temperature cycling and humidity exposure. For laboratory research use only.
Literature references
Selected PubMed record on ipamorelin, scientific background only, not claims about our product. PMID 9849822: ipamorelin, the first selective growth hormone secretagogue. Open any record at https://pubmed.ncbi.nlm.nih.gov/PMID/ . More: https://pubmed.ncbi.nlm.nih.gov/?term=ipamorelin
For laboratory research use only. Not for human or veterinary use. Nothing on this page is medical advice.
